Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 7, 2019

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions

Laryngeal Squamous Cell CarcinomaStage II Laryngeal Cancer AJCC v8Stage III Laryngeal Cancer AJCC v8

Interventions

DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IV

DRUG

Docetaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER